| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| Tyrphostin B42 (AG-490); Tyrphostin B42 (AG-490) | CFN60113 | 133550-30-8 | C17H14N2O3 = 294.30 | 5mg | QQ客服：3257982914 |
| GSK2606414; GSK2606414 | CFN60114 | 1337531-36-8 | C24H20F3N5O = 451.44 | 5mg | QQ客服：2159513211 |
| 盐酸伊立替康三水合物; Irinotecan HCI Trihydrate | CFN60115 | 136572-09-3 | C33H38N4O6.HCl.3H2O = 677.18 | 5mg | QQ客服：2056216494 |
| RGFP966; RGFP966 | CFN60116 | 1396841-57-8 | C21H19FN4O = 362.4 | 5mg | QQ客服：215959384 |
| Tazemetostat (EPZ-6438); Tazemetostat (EPZ-6438) | CFN60117 | 1403254-99-8 | C34H44N4O4 = 572.74 | 5mg | QQ客服：2056216494 |
| JNK-IN-8; JNK-IN-8 | CFN60118 | 1410880-22-6 | C29H29N7O2 = 507.59 | 5mg | QQ客服：215959384 |
| 奥斯替尼; Osimertinib (AZD9291) | CFN60119 | 1421373-65-0 | C28 H33 N7 O2 = 499.61 | 5mg | QQ客服：1457312923 |
| SH-4-54; SH-4-54 | CFN60120 | 1456632-40-8 | C29H27F5N2O5S = 610.59 | 5mg | QQ客服：2159513211 |
| SB202190 (FHPI); SB202190 (FHPI) | CFN60121 | 152121-30-7 | C20H14N3OF = 331.34 | 5mg | QQ客服：215959384 |
| Temsirolimus (CCI-779); Temsirolimus (CCI-779) | CFN60122 | 162635-04-3 | C56H87NO16 = 1030.29 | 5mg | QQ客服：2159513211 |
| 塞来昔布; Celecoxib | CFN60123 | 169590-42-5 | C17H14F3N3O2S = 381.37 | 5mg | QQ客服：2056216494 |
| 恩扎妥林; Enzastaurin (LY317615) | CFN60124 | 170364-57-5 | C32H29N5O2 = 515.61 | 5mg | QQ客服：2056216494 |
| PP2 (AG 1879); PP2 (AG 1879) | CFN60125 | 172889-27-9 | C15H16ClN5 = 301.77 | 5mg | QQ客服：3257982914 |
| Roscovitine; Roscovitine (CYC202) | CFN60126 | 186692-46-6 | C19H26N6O = 354.45 | 5mg | QQ客服：215959384 |
| 泊马度胺; Pomalidomide | CFN60127 | 19171-19-8 | C13H11N3O4 = 273.24 | 5mg | QQ客服：215959384 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)